-
1
-
-
33750499711
-
-
LIPWORTH L TR, MCLAUGHLIN JK: The epidemiology of renal cell carcinoma. J. Urol. (2006) 176:2353-2358. Detailed and up-to-date information on RCC epidemiology.
-
LIPWORTH L TR, MCLAUGHLIN JK: The epidemiology of renal cell carcinoma. J. Urol. (2006) 176:2353-2358. Detailed and up-to-date information on RCC epidemiology.
-
-
-
-
2
-
-
33645526144
-
Cancer statistics, 2006
-
JEMAL A, SIEGEL R, WARD E et al.: Cancer statistics, 2006. CA Cancer J. Clin. (2006) 56(2):106-130.
-
(2006)
CA Cancer J. Clin
, vol.56
, Issue.2
, pp. 106-130
-
-
JEMAL, A.1
SIEGEL, R.2
WARD, E.3
-
3
-
-
0003405565
-
SEER Cancer Sratistics Review, 1973-1999
-
Ries LA, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards BK Eds, National Cancer Institute, Bethesda, MD, USA
-
RIES LA, EISNER M, KOSARY CL et al.: SEER Cancer Sratistics Review, 1973-1999. In: SEER Cancer Statistics Review, 1973-1999. Ries LA, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards BK (Eds), National Cancer Institute, Bethesda, MD, USA (2002).
-
(2002)
SEER Cancer Statistics Review, 1973-1999
-
-
RIES, L.A.1
EISNER, M.2
KOSARY, C.L.3
-
4
-
-
0036251451
-
Global increases in kidney cancer incidence, 1973-1992
-
MATHEW A, DEVESA SS, FRAUMENI JF JR, CHOW WH: Global increases in kidney cancer incidence, 1973-1992. Eur. J. Cancer Prev. (2002) 11(2):171-178.
-
(2002)
Eur. J. Cancer Prev
, vol.11
, Issue.2
, pp. 171-178
-
-
MATHEW, A.1
DEVESA, S.S.2
FRAUMENI JF JR, C.W.3
-
6
-
-
84965188394
-
-
COPPIN C, PORZSOLT F, AWA A et al.: Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev. (2005) (1):CD001425. This article summarizes results of all randomized clinical trials of immunotherapy in mRCC.
-
COPPIN C, PORZSOLT F, AWA A et al.: Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev. (2005) (1):CD001425. This article summarizes results of all randomized clinical trials of immunotherapy in mRCC.
-
-
-
-
7
-
-
0036190056
-
Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: An experience of 405 cases
-
AMIN MB, AMIN MB, TAMBOLI P et al.: Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am. J. Surg. Pathol. (2002) 26(3):281-291.
-
(2002)
Am. J. Surg. Pathol
, vol.26
, Issue.3
, pp. 281-291
-
-
AMIN, M.B.1
AMIN, M.B.2
TAMBOLI, P.3
-
8
-
-
2142853538
-
Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma
-
BECK SD, PATEL MI, SNYDER ME et al.: Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann. Surg. Oncol. (2004) 11(1):71-77.
-
(2004)
Ann. Surg. Oncol
, vol.11
, Issue.1
, pp. 71-77
-
-
BECK, S.D.1
PATEL, M.I.2
SNYDER, M.E.3
-
10
-
-
33846148701
-
Sorafenib in advanced clear-cell renal-cell carcinoma
-
ESCUDIER B, EISEN T, STADLER WM et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. (2007) 356(2):125-134.
-
(2007)
N. Engl. J. Med
, vol.356
, Issue.2
, pp. 125-134
-
-
ESCUDIER, B.1
EISEN, T.2
STADLER, W.M.3
-
11
-
-
33846181370
-
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
-
MOTZER RJ, HUTSON TE, TOMCZAK P et al.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. (2007) 356(2):115-124.
-
(2007)
N. Engl. J. Med
, vol.356
, Issue.2
, pp. 115-124
-
-
MOTZER, R.J.1
HUTSON, T.E.2
TOMCZAK, P.3
-
13
-
-
0019991789
-
Spontaneous regression of metastatic renal cell carcinoma
-
SNOW RM, SCHELLHAMMER PF: Spontaneous regression of metastatic renal cell carcinoma. Urology (1982) 20(2):177-181.
-
(1982)
Urology
, vol.20
, Issue.2
, pp. 177-181
-
-
SNOW, R.M.1
SCHELLHAMMER, P.F.2
-
14
-
-
0017361999
-
The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma
-
MONTIE JE, STEWART BH, STRAFFON RA et al.: The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J. Urol. (1977) 117(3):272-275.
-
(1977)
J. Urol
, vol.117
, Issue.3
, pp. 272-275
-
-
MONTIE, J.E.1
STEWART, B.H.2
STRAFFON, R.A.3
-
15
-
-
7144255510
-
Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group
-
GLEAVE ME, ELHILALI M, FRADET Y et al.: Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N. Engl. J. Med. (1998) 338(18):1265-1271.
-
(1998)
N. Engl. J. Med
, vol.338
, Issue.18
, pp. 1265-1271
-
-
GLEAVE, M.E.1
ELHILALI, M.2
FRADET, Y.3
-
16
-
-
0024539002
-
Unexplained sponraneous regression and alpha-interferon as treatment for metastatic renal carcinoma
-
OLIVER RT, NETHERSELL AB, BOTTOMLEY JM: Unexplained sponraneous regression and alpha-interferon as treatment for metastatic renal carcinoma. Br. J. Urol. (1989) 63(2):128-131.
-
(1989)
Br. J. Urol
, vol.63
, Issue.2
, pp. 128-131
-
-
OLIVER, R.T.1
NETHERSELL, A.B.2
BOTTOMLEY, J.M.3
-
17
-
-
0035818877
-
Nephrecromy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer
-
FLANIGAN RC, SALMON SE, BLUMENSTEIN BA et al.: Nephrecromy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl. J. Med. (2001) 345(23):1655- 1659.
-
(2001)
N Engl. J. Med
, vol.345
, Issue.23
, pp. 1655-1659
-
-
FLANIGAN, R.C.1
SALMON, S.E.2
BLUMENSTEIN, B.A.3
-
18
-
-
0035934596
-
Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: A randomised trial
-
MICKISCH GH, GARIN A, VAN POPPEL H, DE PRIJCK L, SYLVESTER R: Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet (2001) 358(9286):966-970.
-
(2001)
Lancet
, vol.358
, Issue.9286
, pp. 966-970
-
-
MICKISCH, G.H.1
GARIN, A.2
VAN POPPEL, H.3
DE PRIJCK, L.4
SYLVESTER, R.5
-
20
-
-
0024237573
-
Tumor-infiltrating lymphocytes in patients with renal-cell carcinoma
-
FINKE JH, TUBBS R, CONNELLY B, PONTES E, MONTIE J: Tumor-infiltrating lymphocytes in patients with renal-cell carcinoma. Ann. NY Acad. Sci. (1988) 532:387-394.
-
(1988)
Ann. NY Acad. Sci
, vol.532
, pp. 387-394
-
-
FINKE, J.H.1
TUBBS, R.2
CONNELLY, B.3
PONTES, E.4
MONTIE, J.5
-
21
-
-
0141761508
-
Tumor escape from immune response: Mechanisms and targets of activity
-
GABRILOVICH D, PISAREV V: Tumor escape from immune response: mechanisms and targets of activity. Curr. Drug Targets (2003) 4(7):525-536.
-
(2003)
Curr. Drug Targets
, vol.4
, Issue.7
, pp. 525-536
-
-
GABRILOVICH, D.1
PISAREV, V.2
-
22
-
-
0036638978
-
Immunotherapy of metastatic renal cell cancer
-
FISHMAN M, SEIGNE J: Immunotherapy of metastatic renal cell cancer. Cancer Control (2002) 9(4):293-304.
-
(2002)
Cancer Control
, vol.9
, Issue.4
, pp. 293-304
-
-
FISHMAN, M.1
SEIGNE, J.2
-
24
-
-
0033514050
-
Interferon-alpha and survival in metastatic renal carcinoma: Early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators
-
NO AUTHORS LISTED: Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet (1999) 353(9146):14-17.
-
(1999)
Lancet
, vol.353
, Issue.9146
, pp. 14-17
-
-
AUTHORS LISTED, N.1
-
25
-
-
0031804783
-
The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon
-
SMALL EJ, WEISS GR, MALIK UK et al.: The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon. Cancer J. Sci. Am. (1998) 4(3):162-167.
-
(1998)
Cancer J. Sci. Am
, vol.4
, Issue.3
, pp. 162-167
-
-
SMALL, E.J.1
WEISS, G.R.2
MALIK, U.K.3
-
26
-
-
0031406878
-
High-dose aldesleukin in renal cell carcinoma: Long-term survival update
-
FISHER RI, ROSENBERG SA, SZNOL M, PARKINSON DR, FYFE G: High-dose aldesleukin in renal cell carcinoma: long-term survival update. Cancer J. Sci. Am. (1997) 3(Suppl. 1):S70-S72.
-
(1997)
Cancer J. Sci. Am
, vol.3
, Issue.SUPPL. 1
-
-
FISHER, R.I.1
ROSENBERG, S.A.2
SZNOL, M.3
PARKINSON, D.R.4
FYFE, G.5
-
27
-
-
0028266553
-
Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2
-
ROSENBERG SA, YANG JC, TOPALIAN SL et al.: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA (1994) 271(12):907-913.
-
(1994)
JAMA
, vol.271
, Issue.12
, pp. 907-913
-
-
ROSENBERG, S.A.1
YANG, J.C.2
TOPALIAN, S.L.3
-
28
-
-
0032471712
-
Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: Identification of the antigens mediating response
-
ROSENBERG SA, YANG JC, WHITE DE, STEINBERG SM: Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann. Surg. (1998) 228(3):307-319.
-
(1998)
Ann. Surg
, vol.228
, Issue.3
, pp. 307-319
-
-
ROSENBERG, S.A.1
YANG, J.C.2
WHITE, D.E.3
STEINBERG, S.M.4
-
29
-
-
16644401873
-
Randomized Phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
-
MCDERMOTT DF, REGAN MM, CLARK JI et al.: Randomized Phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol. (2005) 23(1):133-141.
-
(2005)
J. Clin. Oncol
, vol.23
, Issue.1
, pp. 133-141
-
-
MCDERMOTT, D.F.1
REGAN, M.M.2
CLARK, J.I.3
-
30
-
-
0042914703
-
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer
-
YANG JC, SHERRY RM, STEINBERG SM et al.: Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. (2003) 21(16):3127-3132.
-
(2003)
J. Clin. Oncol
, vol.21
, Issue.16
, pp. 3127-3132
-
-
YANG, J.C.1
SHERRY, R.M.2
STEINBERG, S.M.3
-
31
-
-
33748686758
-
ReGel polymer-based delivery of interleukin-2 as a cancer treatment
-
SAMLOWSKI WE, MCGREGOR JR, JUREK M et al.: ReGel polymer-based delivery of interleukin-2 as a cancer treatment. J. Immunother. (2006) 29(5):524-535.
-
(2006)
J. Immunother
, vol.29
, Issue.5
, pp. 524-535
-
-
SAMLOWSKI, W.E.1
MCGREGOR, J.R.2
JUREK, M.3
-
32
-
-
0032528446
-
The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor
-
TANNENBAUM CS, TUBBS R, ARMSTRONG D et al.: The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J. Immunol. (1998) 161(2):927-932.
-
(1998)
J. Immunol
, vol.161
, Issue.2
, pp. 927-932
-
-
TANNENBAUM, C.S.1
TUBBS, R.2
ARMSTRONG, D.3
-
33
-
-
7444247430
-
CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease
-
MULLINS IM, SLINGLUFF CL, LEE JK et al.: CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Res. (2004) 64(21):7697- 7701.
-
(2004)
Cancer Res
, vol.64
, Issue.21
, pp. 7697-7701
-
-
MULLINS, I.M.1
SLINGLUFF, C.L.2
LEE, J.K.3
-
34
-
-
0034192078
-
-
SHARMAS, STOLINA M, LOU J et al.: Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J. Immunol. (2000) 164(9):4558-4563.
-
SHARMAS, STOLINA M, LOU J et al.: Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J. Immunol. (2000) 164(9):4558-4563.
-
-
-
-
35
-
-
12744262853
-
CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibirion of vascular remodeling
-
BURDICK MD, MURRAY LA, KEANE MP et al.: CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibirion of vascular remodeling. Am. J. Respir. Crit. Care Med. (2005) 171(3):261-268.
-
(2005)
Am. J. Respir. Crit. Care Med
, vol.171
, Issue.3
, pp. 261-268
-
-
BURDICK, M.D.1
MURRAY, L.A.2
KEANE, M.P.3
-
36
-
-
3042855031
-
The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan
-
YANG J, RICHMOND A: The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. Mol. Ther. (2004) 9(6):846-855.
-
(2004)
Mol. Ther
, vol.9
, Issue.6
, pp. 846-855
-
-
YANG, J.1
RICHMOND, A.2
-
37
-
-
31144468057
-
CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis
-
PAN J, BURDICK MD, BELPERIO JA et al.: CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis. J. Immunol. (2006) 176(3):1456-1464.
-
(2006)
J. Immunol
, vol.176
, Issue.3
, pp. 1456-1464
-
-
PAN, J.1
BURDICK, M.D.2
BELPERIO, J.A.3
-
38
-
-
33845594278
-
Sorafenib plus interferon-α2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG-412
-
GA, USA 2-6 June, Absrract
-
RYAN C, GOLDMAN B, LARA P et al.: Sorafenib plus interferon-α2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG-412. ASCO Annual Meeting. GA, USA (2-6 June 2006) Absrract 4525.
-
(2006)
ASCO Annual Meeting
, pp. 4525
-
-
RYAN, C.1
GOLDMAN, B.2
LARA, P.3
-
39
-
-
34248194715
-
Phase II trial of sorafenib plus inrerferon-alpha 2b (IFN-α2b) as first- or second-line therapy in parients with metastatic renal cell cancer
-
GA, USA 2, 6 June, Abstract 4538
-
GOLLOB JA, RICHMOND T, JONES J et al.: Phase II trial of sorafenib plus inrerferon-alpha 2b (IFN-α2b) as first- or second-line therapy in parients with metastatic renal cell cancer. ASCO Annual Meeting. GA, USA (2 - 6 June 2006) Abstract 4538.
-
(2006)
ASCO Annual Meeting
-
-
GOLLOB, J.A.1
RICHMOND, T.2
JONES, J.3
-
40
-
-
33748363166
-
A Phase III, randomized, 3-arm srudy of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatement of first-line, poor-risk patients with advanced renall cell carcinoma
-
GA, USA 2-6 June, Absrract
-
HUDES G, CARDUCCI M, TOMCZAK P et al.: A Phase III, randomized, 3-arm srudy of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatement of first-line, poor-risk patients with advanced renall cell carcinoma. ASCO Annual Meeting. GA, USA (2-6 June 2006) Absrract LBA4.
-
(2006)
ASCO Annual Meeting
-
-
HUDES, G.1
CARDUCCI, M.2
TOMCZAK, P.3
-
41
-
-
33645816541
-
Phase I/II study of thalidomide in combination with interleukin-2
-
patients with metastatic renal cell carcinoma, :1498-15()6
-
AMATO RJ, MORGAN M, RAWAT A: Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma. Cancer (2006) 106(7):1498-15()6.
-
(2006)
Cancer
, vol.106
, Issue.7
-
-
AMATO, R.J.1
MORGAN, M.2
RAWAT, A.3
-
42
-
-
16844365788
-
Narurally arising Foxp3-expressing CD25+CD4+ regularory T cells in immunological tolerance to self and non-self
-
SAKAGUCHI S: Narurally arising Foxp3-expressing CD25+CD4+ regularory T cells in immunological tolerance to self and non-self. Nat. Immunol. (2005) 6(4):345-352.
-
(2005)
Nat. Immunol
, vol.6
, Issue.4
, pp. 345-352
-
-
SAKAGUCHI, S.1
-
43
-
-
16844362608
-
-
VON BOEHMER H: Mechanisms of suppression by suppressor T cells. Nat. Immunol. (2005) 6(4):338-344. This article clearly depicts the role and function of suppressor T cells.
-
VON BOEHMER H: Mechanisms of suppression by suppressor T cells. Nat. Immunol. (2005) 6(4):338-344. This article clearly depicts the role and function of suppressor T cells.
-
-
-
-
44
-
-
33644784733
-
-
AHMADZADEH M, ROSENBERG SA: IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood (2006) 107(6):2409-2414. This article sheds a new light on the modest clinical efficacy of IL-2 in cancer patients.
-
AHMADZADEH M, ROSENBERG SA: IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood (2006) 107(6):2409-2414. This article sheds a new light on the modest clinical efficacy of IL-2 in cancer patients.
-
-
-
-
45
-
-
34248201884
-
Treg depletion with denileukin difititox (DD) enhances lymphocytosis and eosinophilia in patients treated with high-dose IL-2 (HDIL-2) for metastatic renal cell Cancer (MRCC)
-
GA, USA 2-6 June, Abstract 14627
-
GIDRON A, EKLUND J, MORTONE B et al.: Treg depletion with denileukin difititox (DD) enhances lymphocytosis and eosinophilia in patients treated with high-dose IL-2 (HDIL-2) for metastatic renal cell Cancer (MRCC). ASCO Annual Meeting. GA, USA (2-6 June 2006) Abstract 14627.
-
(2006)
ASCO Annual Meeting
-
-
GIDRON, A.1
EKLUND, J.2
MORTONE, B.3
-
46
-
-
33749424944
-
Vaccines in renal cell carcinoma
-
KUBLER H, VIEWEG J: Vaccines in renal cell carcinoma. Semin. Oncol. (2006) 33(5):614-624.
-
(2006)
Semin. Oncol
, vol.33
, Issue.5
, pp. 614-624
-
-
KUBLER, H.1
VIEWEG, J.2
-
47
-
-
9144238981
-
Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma
-
DILLMAN R, BARTH N, VANDERMOLEN L et al.. Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma. Cancer Biother. Radiopharm. (2004) 19(5):570-580.
-
(2004)
Cancer Biother. Radiopharm
, vol.19
, Issue.5
, pp. 570-580
-
-
DILLMAN, R.1
BARTH, N.2
VANDERMOLEN, L.3
-
48
-
-
0025642936
-
Renal cell carcinoma treated by vaccines for active specific immunotherapy: Correlation of survival with skin testing by autologous tumor cells
-
MCCUNE CS, O'DONNELL RW, MARQUIS DM, SAHASRABUDHE DM: Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells. Cancer Immunol. Immunother. (1990) 32(1):62-66.
-
(1990)
Cancer Immunol. Immunother
, vol.32
, Issue.1
, pp. 62-66
-
-
MCCUNE, C.S.1
O'DONNELL, R.W.2
MARQUIS, D.M.3
SAHASRABUDHE, D.M.4
-
49
-
-
0034068534
-
A randomized Phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: Clinical outcome and analysis of immunological parameters
-
SCHWAAB T, HEANEY JA, SCHNED AR et al.: A randomized Phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters. J. Urol. (2000) 163(4):1322-1327.
-
(2000)
J. Urol
, vol.163
, Issue.4
, pp. 1322-1327
-
-
SCHWAAB, T.1
HEANEY, J.A.2
SCHNED, A.R.3
-
50
-
-
12144288442
-
Immunological effects of granulocyte-macrophage colony-stimulating factor and autologous tumor vaccine in patients with renal cell carcinoma
-
SCHWAAB T, TRETTER CP, GIBSON JJ et al.: Immunological effects of granulocyte-macrophage colony-stimulating factor and autologous tumor vaccine in patients with renal cell carcinoma. J. Urol. (2004) 171(3):1036- 1042.
-
(2004)
J. Urol
, vol.171
, Issue.3
, pp. 1036-1042
-
-
SCHWAAB, T.1
TRETTER, C.P.2
GIBSON, J.J.3
-
51
-
-
0036223749
-
Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma
-
ANTONIA SJ, SEIGNE J, DIAZ J et al.: Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J. Urol. (2002) 167(5):1995-2000.
-
(2002)
J. Urol
, vol.167
, Issue.5
, pp. 1995-2000
-
-
ANTONIA, S.J.1
SEIGNE, J.2
DIAZ, J.3
-
52
-
-
20844460949
-
Allogeneic gene-modified tumour cells in metastatic kidney cancer. Report II
-
PIZZA G, DE VINCI C, LO CONTE G et al.: Allogeneic gene-modified tumour cells in metastatic kidney cancer. Report II. Folia Biol. (Praha) (2004) 50(6):175-183.
-
(2004)
Folia Biol. (Praha)
, vol.50
, Issue.6
, pp. 175-183
-
-
PIZZA, G.1
DE VINCI, C.2
LO CONTE, G.3
-
53
-
-
0030944023
-
Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer
-
SIMONS JW, JAFFEE EM, WEBER CE et al.: Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. (1997) 57(8):1537-1546.
-
(1997)
Cancer Res
, vol.57
, Issue.8
, pp. 1537-1546
-
-
SIMONS, J.W.1
JAFFEE, E.M.2
WEBER, C.E.3
-
54
-
-
4644299284
-
Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: Clinical and immunological findings
-
TANI K, AZUMA M, NAKAZAKI Y et al.. Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings. Mol. Ther. (2004) 10(4):799-816.
-
(2004)
Mol. Ther
, vol.10
, Issue.4
, pp. 799-816
-
-
TANI, K.1
AZUMA, M.2
NAKAZAKI, Y.3
-
55
-
-
30144444279
-
Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells
-
DANNULL J, SU Z, RIZZIERI D et al.: Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. (2005) 115(12):3623-3633.
-
(2005)
J. Clin. Invest
, vol.115
, Issue.12
, pp. 3623-3633
-
-
DANNULL, J.1
SU, Z.2
RIZZIERI, D.3
-
56
-
-
0038066552
-
Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells
-
SU Z, DANNULL J, HEISER A et al.: Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. (2003) 63(9):2127- 2133.
-
(2003)
Cancer Res
, vol.63
, Issue.9
, pp. 2127-2133
-
-
SU, Z.1
DANNULL, J.2
HEISER, A.3
-
57
-
-
10744232378
-
-
GITLITZ BJ, BELLDEGRUN AS, ZISMAN A et al.: A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J. Immunother. (2003) 26(5):412-419.
-
GITLITZ BJ, BELLDEGRUN AS, ZISMAN A et al.: A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J. Immunother. (2003) 26(5):412-419.
-
-
-
-
58
-
-
0036845714
-
Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells
-
HOLTL L, ZELLE-RIESER C, GANDER H et al.: Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin. Cancer Res. (2002) 8(11):3369-3376.
-
(2002)
Clin. Cancer Res
, vol.8
, Issue.11
, pp. 3369-3376
-
-
HOLTL, L.1
ZELLE-RIESER, C.2
GANDER, H.3
-
59
-
-
19244365218
-
Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: A Phase I study
-
OOSTERWIJK-WAKKA JC, TIEMESSEN DM, BLEUMER I et al.: Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a Phase I study. J. Immunother. (2002) 25(6):500-508.
-
(2002)
J. Immunother
, vol.25
, Issue.6
, pp. 500-508
-
-
OOSTERWIJK-WAKKA, J.C.1
TIEMESSEN, D.M.2
BLEUMER, I.3
-
60
-
-
3242666031
-
Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses
-
AVIGAN D, VASIR B, GONG J et al.: Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin. Cancer Res. (2004) 10(14):4699-4708.
-
(2004)
Clin. Cancer Res
, vol.10
, Issue.14
, pp. 4699-4708
-
-
AVIGAN, D.1
VASIR, B.2
GONG, J.3
-
61
-
-
4043156133
-
Dendritic cell-tumor cell hybrid vaccination for metastatic cancer
-
BARBUTO JA, ENSINA LF, NEVES AR et al.: Dendritic cell-tumor cell hybrid vaccination for metastatic cancer. Cancer Immunol. Immunother. (2004) 53(12):1111-1118.
-
(2004)
Cancer Immunol. Immunother
, vol.53
, Issue.12
, pp. 1111-1118
-
-
BARBUTO, J.A.1
ENSINA, L.F.2
NEVES, A.R.3
-
62
-
-
0037457018
-
Allogeneic dendritic cells fused with tumor cells: Preclinical results and outcome of a clinical Phase I/II trial in patients with metastatic renal cell carcinoma
-
MARTEN A, RENOTH S, HEINICKE T et al.: Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical Phase I/II trial in patients with metastatic renal cell carcinoma. Hum. Gene Ther. (2003) 14(5):483-494.
-
(2003)
Hum. Gene Ther
, vol.14
, Issue.5
, pp. 483-494
-
-
MARTEN, A.1
RENOTH, S.2
HEINICKE, T.3
-
63
-
-
33746374452
-
Protective effect of irradiated renal carcinoma expressing hepatitis B surface antigen against renal-cell carcinoma-mediated tumors
-
MOON Y, CHO SG, LEE JW et al.: Protective effect of irradiated renal carcinoma expressing hepatitis B surface antigen against renal-cell carcinoma-mediated tumors. Cancer Biother. Radiopharm. (2006) 21(3):211-216.
-
(2006)
Cancer Biother. Radiopharm
, vol.21
, Issue.3
, pp. 211-216
-
-
MOON, Y.1
CHO, S.G.2
LEE, J.W.3
-
64
-
-
10744230275
-
-
JOCHAM D, RICHTER A, HOFFMANN L et al.: Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrecromy: Phase III, randomised controlled trial. Lancet (2004) 363(9409):594-599. The first trial demonstrating the efficacy of immunotherapy (autologous vaccine) in an adjuvant setting in RCC patients.
-
JOCHAM D, RICHTER A, HOFFMANN L et al.: Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrecromy: Phase III, randomised controlled trial. Lancet (2004) 363(9409):594-599. The first trial demonstrating the efficacy of immunotherapy (autologous vaccine) in an adjuvant setting in RCC patients.
-
-
-
-
65
-
-
19944429320
-
Phase I/II trial of gene therapy with autologous tumor cells modified with tag7/PGRP-S gene in patients with disseminated solid tumors: Miscellaneous tumors
-
MOISEYENKO VM, DANILOV AO, BALDUEVA IA et al.: Phase I/II trial of gene therapy with autologous tumor cells modified with tag7/PGRP-S gene in patients with disseminated solid tumors: miscellaneous tumors. Ann. Oncol. (2005) 16(1):162-168.
-
(2005)
Ann. Oncol
, vol.16
, Issue.1
, pp. 162-168
-
-
MOISEYENKO, V.M.1
DANILOV, A.O.2
BALDUEVA, I.A.3
-
66
-
-
0036909829
-
Genetically modified dendritic cells-a new, promising cancer treatment strategy?
-
WYSOCKI PJ, GRABARCZYK P, MACKIEWICZ-WYSOCKA M, KOWALCZYK DW, MACKIEWICZ A: Genetically modified dendritic cells-a new, promising cancer treatment strategy? Expert Opin. Biol. Ther. (2002) 2(8):835-845.
-
(2002)
Expert Opin. Biol. Ther
, vol.2
, Issue.8
, pp. 835-845
-
-
WYSOCKI, P.J.1
GRABARCZYK, P.2
MACKIEWICZ-WYSOCKA, M.3
KOWALCZYK, D.W.4
MACKIEWICZ, A.5
-
67
-
-
1642456671
-
Dendritic cells: Immunobiology and cancer immunotherapy
-
ARDAVIN C, AMIGORENA S, REIS E SOUSA C: Dendritic cells: immunobiology and cancer immunotherapy. Immunity (2004) 20(1):17-23.
-
(2004)
Immunity
, vol.20
, Issue.1
, pp. 17-23
-
-
ARDAVIN, C.1
AMIGORENA, S.2
REIS, E.3
SOUSA, C.4
-
69
-
-
0032546352
-
Dendritic cells and the control of immunity
-
BANCHEREAU J, STEINMAN RM: Dendritic cells and the control of immunity. Nature (1998) 392(6673):245-252.
-
(1998)
Nature
, vol.392
, Issue.6673
, pp. 245-252
-
-
BANCHEREAU, J.1
STEINMAN, R.M.2
-
70
-
-
0035139983
-
Danger signals: SOS to the immune system
-
GALLUCCI S, MATZINGER P: Danger signals: SOS to the immune system. Curr. Opin. Immunol. (2001) 13(1):114-119.
-
(2001)
Curr. Opin. Immunol
, vol.13
, Issue.1
, pp. 114-119
-
-
GALLUCCI, S.1
MATZINGER, P.2
-
71
-
-
3042628507
-
CpG immunostimulatory oligodeoxynucleotide 1826 enhances antitumor effect of interleukin 12 gene-modified tumor vaccine in a melanoma model in mice
-
SWITAJ T, JALILI A, JAKUBOWSKA AB et al.: CpG immunostimulatory oligodeoxynucleotide 1826 enhances antitumor effect of interleukin 12 gene-modified tumor vaccine in a melanoma model in mice. Clin. Cancer Res. (2004) 10(12 Pt 1):4165-4175.
-
(2004)
Clin. Cancer Res
, vol.10
, Issue.12 PART 1
, pp. 4165-4175
-
-
SWITAJ, T.1
JALILI, A.2
JAKUBOWSKA, A.B.3
-
72
-
-
12944255776
-
-
CHAGNON F, TANGUAY S, OZDAL OL et al.: Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides. Clin. Cancer Res. (2005) 11(3):1302-1311.
-
CHAGNON F, TANGUAY S, OZDAL OL et al.: Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides. Clin. Cancer Res. (2005) 11(3):1302-1311.
-
-
-
-
73
-
-
34248139399
-
Treatment of advanced renal cell carcinoma with tumor lysate pulsed IL-12 secreting autologous dendritic cells
-
GA, USA 2-6 June, Abstract 14585
-
WIMPISSINGER T, FELZMANN T, HUGEL H, FUNOVICS P, STACKL W: Treatment of advanced renal cell carcinoma with tumor lysate pulsed IL-12 secreting autologous dendritic cells. ASCO Annual Meeting. GA, USA (2-6 June 2006) Abstract 14585.
-
(2006)
ASCO Annual Meeting
-
-
WIMPISSINGER, T.1
FELZMANN, T.2
HUGEL, H.3
FUNOVICS, P.4
STACKL, W.5
-
74
-
-
33745247366
-
Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients
-
WIERECKY J, MULLER MR, WIRTHS S et al.: Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res. (2006) 66(11):5910-5918.
-
(2006)
Cancer Res
, vol.66
, Issue.11
, pp. 5910-5918
-
-
WIERECKY, J.1
MULLER, M.R.2
WIRTHS, S.3
-
75
-
-
0347100681
-
Phase II study of autologous tumor derived heat shock protein-peptide complex vaccine (HSPPC-96) for patients with metastatic renal cell carcinoma
-
ASSIKI V, DALIANI D, PAGLIARO L et al.: Phase II study of autologous tumor derived heat shock protein-peptide complex vaccine (HSPPC-96) for patients with metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. (2003) 22:386.
-
(2003)
Proc. Am. Soc. Clin. Oncol
, vol.22
, pp. 386
-
-
ASSIKI, V.1
DALIANI, D.2
PAGLIARO, L.3
-
76
-
-
11144354471
-
A Phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients
-
BLEUMER I, KNUTH A, OOSTERWIJK E et al.: A Phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br. J. Cancer (2004) 90(5):985-990.
-
(2004)
Br. J. Cancer
, vol.90
, Issue.5
, pp. 985-990
-
-
BLEUMER, I.1
KNUTH, A.2
OOSTERWIJK, E.3
-
77
-
-
33646862241
-
Stimulation through CD40 on mouse and human renal cell carcinomas triggers cytokine production, leukocyte recruitment, and antitumor responses that can be independent of host CD40 expression
-
SHORTS L, WEISS JM, LEE JK et al.: Stimulation through CD40 on mouse and human renal cell carcinomas triggers cytokine production, leukocyte recruitment, and antitumor responses that can be independent of host CD40 expression. J. Immunol. (2006) 176(11):6543-6552.
-
(2006)
J. Immunol
, vol.176
, Issue.11
, pp. 6543-6552
-
-
SHORTS, L.1
WEISS, J.M.2
LEE, J.K.3
-
78
-
-
28844487782
-
Tumor regression in patients with metastatic renal cancer treated with a monoclonal antibody to CTLA4 (MDX-010)
-
Orlando, FL, USA 13-17 May, Abstract 2501
-
YANG J, BECK K, BLANSFIELD J et al.: Tumor regression in patients with metastatic renal cancer treated with a monoclonal antibody to CTLA4 (MDX-010). ASCO Annual Meeting. Orlando, FL, USA (13-17 May 2005). Abstract 2501.
-
(2005)
ASCO Annual Meeting
-
-
YANG, J.1
BECK, K.2
BLANSFIELD, J.3
-
79
-
-
33744792341
-
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4
-
BECK KE, BLANSFIELD JA, TRAN KQ et al.: Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J. Clin. Oncol. (2006) 24(15):2283-2289.
-
(2006)
J. Clin. Oncol
, vol.24
, Issue.15
, pp. 2283-2289
-
-
BECK, K.E.1
BLANSFIELD, J.A.2
TRAN, K.Q.3
-
80
-
-
0027529476
-
Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer
-
ROSENBERG SA, LOTZE MT, YANG JC et al.: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl Cancer Inst. (1993) 85(8):622-632.
-
(1993)
J. Natl Cancer Inst
, vol.85
, Issue.8
, pp. 622-632
-
-
ROSENBERG, S.A.1
LOTZE, M.T.2
YANG, J.C.3
-
81
-
-
34247260551
-
Immunotherapy for renal cell cancer
-
YANG JC, CHILDS R: Immunotherapy for renal cell cancer. J. Clin. Oncol. (2006) 24(35):5576-5583.
-
(2006)
J. Clin. Oncol
, vol.24
, Issue.35
, pp. 5576-5583
-
-
YANG, J.C.1
CHILDS, R.2
-
82
-
-
0035009499
-
Gamma/delta T cells provide innate immunity against renal cell carcinoma
-
KOBAYASHI H, TANAKA Y, YAGI J, TOMA H, UCHIYAMA T: Gamma/delta T cells provide innate immunity against renal cell carcinoma. Cancer Immunol. Immunother. (2001) 50(3):115-124.
-
(2001)
Cancer Immunol. Immunother
, vol.50
, Issue.3
, pp. 115-124
-
-
KOBAYASHI, H.1
TANAKA, Y.2
YAGI, J.3
TOMA, H.4
UCHIYAMA, T.5
-
83
-
-
33846813974
-
Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: A pilot study
-
KOBAYASHI H, TANAKA Y, YAGI J et al.: Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother. (2006) 56(4):469-476.
-
(2006)
Cancer Immunol Immunother
, vol.56
, Issue.4
, pp. 469-476
-
-
KOBAYASHI, H.1
TANAKA, Y.2
YAGI, J.3
-
84
-
-
0036019378
-
Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer
-
LAMERS CH, WILLEMSEN RA, LUIDER BA, DEBETS R, BOLHUIS RL: Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer. Cancer Gene Ther. (2002) 9(7):613-623.
-
(2002)
Cancer Gene Ther
, vol.9
, Issue.7
, pp. 613-623
-
-
LAMERS, C.H.1
WILLEMSEN, R.A.2
LUIDER, B.A.3
DEBETS, R.4
BOLHUIS, R.L.5
-
85
-
-
33646440024
-
Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: First clinical experience
-
LAMERS CH, SLEIJFER S, VULTO AG et al.: Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. (2006) 24(13):e20-e22.
-
(2006)
J. Clin. Oncol
, vol.24
, Issue.13
-
-
LAMERS, C.H.1
SLEIJFER, S.2
VULTO, A.G.3
-
86
-
-
0032607572
-
Historical markers in the development of allogeneic hematopoietic cell transplantation
-
THOMAS ED, BLUME KG: Historical markers in the development of allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant. (1999) 5(6):341-346.
-
(1999)
Biol. Blood Marrow Transplant
, vol.5
, Issue.6
, pp. 341-346
-
-
THOMAS, E.D.1
BLUME, K.G.2
-
87
-
-
0025678601
-
Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients
-
KOLB HJ, MITTERMULLER J, CLEMM C et al.: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood (1990) 76(12):2462-2465.
-
(1990)
Blood
, vol.76
, Issue.12
, pp. 2462-2465
-
-
KOLB, H.J.1
MITTERMULLER, J.2
CLEMM, C.3
-
88
-
-
33745588857
-
-
BARKHOLT L, BREGNI M, REMBERGER M et al.: Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Ann. Oncol. (2006) 17(7):1134-1140. This article reports the largest experience to date of allogeneic HSCT for mRCC.
-
BARKHOLT L, BREGNI M, REMBERGER M et al.: Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Ann. Oncol. (2006) 17(7):1134-1140. This article reports the largest experience to date of allogeneic HSCT for mRCC.
-
-
-
-
89
-
-
20144384975
-
Allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of metastatic renal cell carcinoma - single center experience
-
RZEPECKI P, ZOLNIEREK J, SAROSIEK T, LANGIEWICZ P, SZCZYLIK C: Allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of metastatic renal cell carcinoma - single center experience. Neoplasma (2005) 52(3):238-242.
-
(2005)
Neoplasma
, vol.52
, Issue.3
, pp. 238-242
-
-
RZEPECKI, P.1
ZOLNIEREK, J.2
SAROSIEK, T.3
LANGIEWICZ, P.4
SZCZYLIK, C.5
-
90
-
-
8744315211
-
Antigenic targets for renal cell carcinoma immunotherapy
-
VIEWEG J, JACKSON A: Antigenic targets for renal cell carcinoma immunotherapy. Expert Opin. Biol. Ther. (2004) 4(11):1791-1801.
-
(2004)
Expert Opin. Biol. Ther
, vol.4
, Issue.11
, pp. 1791-1801
-
-
VIEWEG, J.1
JACKSON, A.2
-
91
-
-
5644255720
-
Human cancer gene therapy with cytokine gene-modified cells
-
WYSOCKI PJ, KARCZEWSKA-DZIONK A, MACKIEWICZ-WYSOCKA M, MACKIEWICZ A: Human cancer gene therapy with cytokine gene-modified cells. Expert Opin. Biol. Ther. (2004) 4(10):1595-1607.
-
(2004)
Expert Opin. Biol. Ther
, vol.4
, Issue.10
, pp. 1595-1607
-
-
WYSOCKI, P.J.1
KARCZEWSKA-DZIONK, A.2
MACKIEWICZ-WYSOCKA, M.3
MACKIEWICZ, A.4
-
92
-
-
33746074464
-
Captopril, an angiotensin-converting enzyme inhibitor, promotes growth of immunogenic tumors in mice
-
WYSOCKI PJ, KWIATKOWSKA EP, KAZIMIERCZAK U et al.: Captopril, an angiotensin-converting enzyme inhibitor, promotes growth of immunogenic tumors in mice. Clin. Cancer Res. (2006) 12(13):4095-4102.
-
(2006)
Clin. Cancer Res
, vol.12
, Issue.13
, pp. 4095-4102
-
-
WYSOCKI, P.J.1
KWIATKOWSKA, E.P.2
KAZIMIERCZAK, U.3
-
93
-
-
33646357786
-
-
MICHAELIS LC, RATAIN MJ: Measuring response in a post-RECIST world: from black and white to shades of grey. Nat. Rev. Cancer (2006) 6(5):409-414. This article summarizes the drawbacks of the existing tumor response evaluation criteria (RECIST) if used for non-chemotherapy-based clinical trials.
-
MICHAELIS LC, RATAIN MJ: Measuring response in a post-RECIST world: from black and white to shades of grey. Nat. Rev. Cancer (2006) 6(5):409-414. This article summarizes the drawbacks of the existing tumor response evaluation criteria (RECIST) if used for non-chemotherapy-based clinical trials.
-
-
-
-
94
-
-
23844469804
-
Phase II oncology trials: Let's be positive
-
RATAIN MJ: Phase II oncology trials: let's be positive. Clin. Cancer Res. (2005) 11(16):5661-5662.
-
(2005)
Clin. Cancer Res
, vol.11
, Issue.16
, pp. 5661-5662
-
-
RATAIN, M.J.1
-
95
-
-
16544380415
-
Phase II srudies of modern drugs directed against new targets: If you are fazed, too, then resist RECIST
-
RATAIN MJ, ECKHARDT SG: Phase II srudies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J. Clin. Oncol. (2004) 22(22):4442-4445.
-
(2004)
J. Clin. Oncol
, vol.22
, Issue.22
, pp. 4442-4445
-
-
RATAIN, M.J.1
ECKHARDT, S.G.2
-
96
-
-
11144251200
-
Cancer vaccines: Pessimism in check
-
1278-1279; author reply 1279-1280
-
MOCELLIN S, MANDRUZZATO S, BRONTE V, MARINCOLA FM: Cancer vaccines: pessimism in check. Nat. Med. (2004) 10(12):1278-1279; author reply 1279-1280.
-
(2004)
Nat. Med
, vol.10
, Issue.12
-
-
MOCELLIN, S.1
MANDRUZZATO, S.2
BRONTE, V.3
MARINCOLA, F.M.4
-
97
-
-
33744954585
-
Sunitinib in patients with metastatic renal cell carcinoma
-
MOTZER RJ, RINI BI, BUKOWSKI RM et al.: Sunitinib in patients with metastatic renal cell carcinoma. JAMA (2006) 295(21):2516-2524.
-
(2006)
JAMA
, vol.295
, Issue.21
, pp. 2516-2524
-
-
MOTZER, R.J.1
RINI, B.I.2
BUKOWSKI, R.M.3
|